Sanofi-Aventis and partner Oxford Biomedica say the TroVax vaccine discovered by the latter has failed to reach its targets in a late-stage trial in renal cancer, news which has caused the UK firm’s share price to collapse.
Oxford BioMedica said the independent data safety monitoring board for the 733-patient Phase III TRIST study of TroVax in renal cancer has recommended that the trial should continue but that further vaccinations be discontinued, following its fourth interim review. The DSMB advised that TroVax administered according to the protocol will not meet the predefined primary efficacy endpoint, “but there is important scientific merit and more to be learned by additional follow-up of all patients.”
More
No comments:
Post a Comment